The St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project (PCGP) has identified critical driver genes that account for disease-related alterations in a range of uncommon low-grade neuroepithelial tumors. These diverse brain tumors grow slowly and are found in some children and young adults, many of whom have a history of epilepsy. The study describing the genetic alterations has just been published online in the journal Acta Neuropathologica. The study represents an extension of the authors’ earlier PCGP analysis of common low-grade gliomas published in Nature Genetics in 2014.
The researchers identified three single-driver genetic alterations known as BRAF, FGFR and MYB that occur at high frequency in these types of tumors and which correspond to the pathologic features of the disease. The findings offer improved options not only for characterization and diagnosis of these low-grade neuroepithelial tumors but also for new treatment options.
“Low-grade neuroepithelial tumors are varied, and some types are rare, particularly those associated with chronic epilepsy. Until now, genetic alterations driving the growth of many of these rare tumors have largely been unknown,” said corresponding author David Ellison, M.D., Ph.D., St. Jude Department of Pathology chair, the study’s principal investigator. “Our findings have shown that many of the tumors we studied are caused by relatively few key genetic alterations, some of which have new drug therapies in development.”
The researchers conducted next-generation DNA sequencing of samples from tumors obtained from 91 patients who had an average age of 10 years. Whole-genome, whole-exome and transcriptome sequencing revealed that 78 percent of these low-grade neuroepithelial tumors could be pinned down to single alterations in the BRAF, FGFR or MYB genes.
Overall survival of patients with common low-grade neuroepithelial tumors is good mainly because such tumors occur in locations amenable to surgical removal. However, a significant number of the less common types of low-grade neuroepithelial tumors are more challenging to remove surgically and may lead to long-term illness and premature death. Therapeutic options are already being tested in clinical trials that target the effects of some of the driver genes identified in the study. This may lead to new treatment options.
Increasingly, the profiling of genetic alterations is being incorporated into the diagnosis of many types of disease. “Our genetic analysis should help the diagnosis of low-grade neuroepithelial tumors that present similar cytological features,” said co-author Richard K. Wilson, Ph.D., director of The McDonnell Genome Institute at Washington University School of Medicine in St. Louis. “Genome sequencing allows us to have more information for each tumor type and can help in classifying some of the tumors that are less amenable to study by other diagnostic methods.”
The co-first authors are Ibrahim Qaddoumi, Wilda Orisme and Ji Wen. The other authors are Teresa Santiago, Kirti Gupta, James D. Dalton, Bo Tang, Kelly Haupfear, Chandanamali Punchihewa, John Easton, Heather Mulder, Kristy Boggs, Ying Shao, Michael Rusch, Jared Becksfort, Pankaj Gupta, Shuoguo Wang, Ryan P. Lee, Daniel Brat, V. Peter Collins, Sonika Dahiya, David George, William Konomos, Kathreena M. Kurian, Kathryn McFadden, Luciano Neder Serafini, Hilary Nickols, Arie Perry, Sheila Shurtleff, Amar Gajjar, Fredrick A. Boop, Paul D. Klimo Jr., Elaine R. Mardis, Suzanne J. Baker, Jinghui Zhang, Gang Wu, James R. Downing and Ruth G. Tatevossian.
The research was funded in part by the Pediatric Cancer Genome Project, including Kay Jewelers, a lead sponsor; and ALSAC.
St. Jude Children’s Research Hospital
St. Jude Children’s Research Hospital is leading the way the world understands, treats and cures childhood cancer and other life-threatening diseases. It is the only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children. Treatments developed at St. Jude have helped push the overall childhood cancer survival rate from 20 percent to 80 percent since the hospital opened more than 50 years ago. St. Jude freely shares the breakthroughs it makes, and every child saved at St. Jude means doctors and scientists worldwide can use that knowledge to save thousands more children. Families never receive a bill from St. Jude for treatment, travel, housing and food — because all a family should worry about is helping their child live. To learn more, visit stjude.org or follow the hospital on Twitter and Instagram at @stjuderesearch.
Washington University School of Medicine’s 2,100 employed and volunteer faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Children’s hospitals. The School of Medicine is one of the leading medical research, teaching and patient-care institutions in the nation, currently ranked sixth in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Children’s hospitals, the School of Medicine is linked to BJC HealthCare.